Keeps Biopharma Q1 2026 Consolidated Revenue Up, Net Profit Turns Positive, Operating Loss Persists

Q1 2026 consolidated revenue: KRW 59.4B (up 46.4% YoY from KRW 40.6B)
Consolidated operating loss: KRW 0.66B (vs operating profit of KRW 0.09B in prior year)
Consolidated net profit: KRW 5.73B (vs net loss of KRW 11.1B in prior year)
Debt-to-equity ratio: 186.14% (similar to 187.01% at year-end 2025, high leverage)
Newly acquired 92% stake in subsidiary Elpispharm Co., Ltd. (Feb 27, 2026, business diversification)
Anti-cancer drug Idetrexed: submitted Phase 2 IND in Korea (Mar 10, 2026)
Oral peptide platform (Oraloid™) in preclinical stage
No separate disclosure on shareholder return policies